PCOS is finally catching up to the science.
What’s happening: Impacting 170M+ women globally, the chronic condition formerly known as polycystic ovary syndrome has been renamed polyendocrine metabolic ovarian syndrome (PMOS) to better reflect root causes and symptoms.
Diagnostic lapse. Previously defined by the presence of irregular ovarian cysts, the condition is linked to long-term health issues like diabetes and infertility. But despite affecting up to 13% of women, ~70% go undiagnosed — while those that do often receive a delayed diagnosis following years of irregular periods, weight gain, and hair thinning.
Misnomer. Although updating guidelines in 2023 to better capture its hormonal and metabolic dysfunction impacting hair, skin, weight, mood, and reproductive health, the condition’s inaccurate moniker still led to delayed detection, missed diagnosis, patient confusion, and inaccessible care.
Finding no link between the condition and abnormal cysts, the rename, informed by 50+ organizations, researchers, and thousands of patient surveys, aims to boost awareness and improve care from test to treatment.
Punchline: Reflecting a shift towards lifelong support, overlooked hormonal conditions like PMOS demand attention and precision care.
